Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Theranostics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The global theranostics market forecast reveals a promising future, with projections of substantial growth driven by technological advancements and the escalating need for precision medicine in cancer care. A comprehensive analysis of the theranostics industry has been added to our expansive online research repository, offering deep insights into the market's trajectory.
Prompted by the fusion of therapy and diagnostics, the theranostics field has seen a remarkable surge. Integrated approaches uniting pharmaceuticals and molecular diagnostics are poised to revolutionize personalized healthcare. The latest findings show prospective growth from $98.91 billion in 2023 to an expected $164.38 billion by 2028, charting a CAGR of 10.5%. This expansion underscores the sector's vitality and its crucial role in advancing treatment modalities for chronic and oncologic diseases.
The report explores key market segments, including the rising emphasis on cancer theranostics and various diseases such as neurological disorders, cardiovascular diseases, and immunological disorders. Investigations into technological segments such as polymerase chain reaction, immunohistochemistry, in-situ hybridization, and sequencing provide perspective on the market's evolution.
Regional Market Overview
- North America stands as a dominant force in the global theranostics market.
- Asia-Pacific is emerging as the fastest-growing region, signaling robust advancements and adoption.
Market Dynamics
Identified Drivers:
- Increasing global cancer prevalence, demanding innovative and personalized treatment strategies.
- Significant investment and support for theranostic research and development activities.
Emerging Trends:
- Advanced molecular imaging ushering in a new era of precision oncology.
- Technological convergence leading to concerted patient engagement and awareness.
- Regulatory support augmenting the development and approval of novel theranostic solutions.
Strategic partnerships and acquisitions are also highlighted, demonstrating the market's vibrant landscape and the drive for innovation among industry leaders.
The extensive report garners an exhaustive understanding of the theranostics market's intricacies, accounting for the revenue generated from genetic testing, targeted therapy services, and companion diagnostics. Highlighting the value chain dynamics, it emphasizes the "factory gate" values contributing to the market's size.
This pivotal market research document sheds light on the transformative journey of the theranostics market, mapping out the path ahead and offering stakeholders detailed market statistics and indispensable knowledge.
A selection of companies mentioned in this report includes
- Abbott Laboratories
- Agilent Technologies Inc.
- AmeriPath Inc
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc
- Astellas Pharma
- Helmholtz Centre for Infection Research
- Radiopharm Theranostics Ltd
- Alpha- Theranostics
- UNIVERZITET U NOVOM SADU
- Cardio-Theranostics LLC
- Curium
- SoFi Technologies Inc.
- Theradiag
- Cell Theranostics
- F. Hoffmann-La Roche AG
- GE HealthCare Technologies Inc
- Qiagen NV
- Foundation Medicine Inc
- Leica Biosystems Nussloch GmBH
- Pfizer Inc.
- Siemens Healthineers
- Advanced Accelerator Applications
- AstraZeneca plc
- Bayer AG
- Bio-Rad Laboratories
- The Bristol-Myers Squibb Company
- Danaher Corporation
- MilliporeSigma
- Illumina Inc.
- Merck KGaA
- Roche Diagnostics Corporation
- PerkinElmer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jap8lc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
